Vote — approved

Steve Gallardo	abstain
Bill Gates	abstain
Clint Hickman	abstain
and Steve Gallardo	yes
and Clint Hickman	yes
Denny Barney	abstain
Steve Chucri	yes

41.AGREEMENT FOR OUTPATIENT SAMPLE PROGRAM WITH ALKERMES, INCAdopt a Resolution which authorizes an Agreement between Alkermes, Inc. and Maricopa County through the Department of Correctional Health Services, for the purpose of a free medication program for psychiatric patients. Approve and authorize, by Resolution, Maricopa County by and through its Department of Correctional Health Services (MCDCHS), to process a non-financial Certification and Request form for ARISTADA Samples with Alkermes, 

Item Text

41. AGREEMENT FOR OUTPATIENT SAMPLE PROGRAM WITH ALKERMES, INC Adopt a Resolution which authorizes an Agreement between Alkermes, Inc. and Maricopa County through the Department of Correctional Health Services, for the purpose of a free medication program for psychiatric patients. Approve and authorize, by Resolution, Maricopa County by and through its Department of Correctional Health Services (MCDCHS), to process a non-financial Certification and Request form for ARISTADA Samples with Alkermes, Inc.; for free samples of ARISTADA. Available doses in four (4) different strengths: 441mg, 662 mg, 882 mg and 1064 mg. This Agreement is non-financial and is effective from June 27, 2018 until June 27, 2023. Long acting injectable (LAI) antipsychotic medications are used frequently in the community for psychiatric conditions, including schizophrenia, schizoaffective disorder, and bipolar disorder. Given the large number of jail inmates with psychiatric conditions who get treated with LAI medications in the community, best practices dictate that these medications be continued in jail for patients who are stable and compliant on LAIs. The cost of LAIs is significant. On average, 200 patients per month are receiving injectable antipsychotic medications in Maricopa County Jails. This comprises 20% of the monthly pharmacy budget for a jail population of 7500. Fortunately, pharmaceutical companies understand the burden that LAIs have on county budgets and have programs designed specifically to provide medications, free of charge, to incarcerated populations. Creating a partnership with these companies will allow for continuity of care on patients, while in jail, who are stable and compliant in the community with LAI medications. It will also allow for ‘new starts’ on patients who are good candidates (either those who have been on LAIs in the past, or who may benefit from doing a trial of LAIs for the first time). (C-26-18-009-3-00)

Attachments (2)